Shimadzu's Response to
the COVID-19 Pandemic

Our Role: Helping People Respond to the Pandemic

The COVID-19 pandemic has brought unprecedented challenges for the communities and economies worldwide, causing a profound effect on the health and well-being of people.

Science is more important now than ever before. Shimadzu Corporation has been committed to contributing to society through science and technology since its founding in 1875.

Today, we see many frontline healthcare workers and researchers focus their efforts toward caring for people, finding a treatment, and developing a vaccine and pharmaceuticals. We will harness the power of science and utilize our full capabilities to support and respond to these efforts.

This website introduces the current efforts and technologies for virus detection, pneumonia diagnosis and drug analysis that Shimadzu can offer in responding to this global pandemic.

Science will get us through this pandemic.

Virus Detection
2019 Novel Coronavirus Detection Kit

Speed and accuracy are crucial for the detection and containment of the SARS-CoV-2 novel coronavirus. Shimadzu has developed the “2019 Novel Coronavirus Detection Kit” based on Shimadzu’s unique gene amplification reagent, Ampdirect® technology for PCR analysis, and the pathogen detection manual from the Japanese National Institute for Infectious Diseases.

As compared to regular kits, this detection kit eliminates the need for RNA extraction and purification and halves the overall time required for PCR detection.

Shimadzu will continue to contribute to measures against infectious diseases by developing reagents that detect pathogens quickly and efficiently.

Quick and simple workflow
  • Kit includes all the reagents needed for immediate PCR analysis
  • Simple and accurate sample preparation
  • Entire workflow completes in little more than an hour
Improved accuracy 
  • Kit includes reference component to check if the amplification was carried out correctly and avoid false negatives

* The 2019 Coronavirus Detection Kit (Research Use Only) is only available in Japan. (As of June 2020)

Contact Us

Message from Shimadzu People

Clinical & Biotechnology Business Unit, Life Science Business Department, Analytical & Measuring Instruments Division Masamitsu Shikata

Clinical & Biotechnology Business Unit, Life Science Business Department, Analytical & Measuring Instruments Division
Masamitsu Shikata

* This interview was conducted in June 2020.

Contributing to PCR Analysis

We have been working on the development of gene-detecting reagents for use in the PCR analysis of infectious diseases. With the spread of COVID-19, the demand for PCR testing has increased, and it is becoming difficult for clinical laboratories to obtain existing reagent kits in Japan. We were eager to assist clinical researchers at the forefront of the struggle against COVID-19 by developing a reagent kit that can detect the new coronavirus. The kit would be based on a proven technology, unique to Shimadzu, which shortens the time required for PCR analysis.

PCR analysis requires amplification of viral genes. Based on our experience in developing reagent kits for detecting pathogens such as norovirus, I initially thought that our technology could be applied to the new coronavirus without much difficulty. However, as development progressed, we found the amplification of the new coronavirus was not as easy as expected. To overcome this obstacle, our team intensified its effort into devising reagent compositions to detect the virus with high sensitivity.

The newly-developed novel coronavirus detection kit (*) eliminates the steps of RNA extraction and purification, significantly reducing the amount of work required to prepare samples. Moreover, it halves the overall time required for PCR detection from over 2 hours to approximately 1 hour. It can detect viruses not only using samples taken from the back of the nose or throat, but also those taken from saliva.

Customers using this product have told us that their workload has been reduced and that they are satisfied with the kit’s performance, as the sensitivity is equivalent to or higher than that of conventional methods.

(*) The kit (Research Use Only) is only available in Japan. (As of June 2020)

Pneumonia Diagnosis
Mobile Digital X-Ray System

In the event of a pandemic infection, like COVID-19, existing CT or fixed X-ray facilities in hospitals may not be easily accessible or disinfected.

For this reason, a “mobile” X-ray system is a very important tool for pneumonia diagnosis as it can be used to examine patients in an isolated patient room or ICU. In addition, a mobile system is easier to disinfect after exams than fixed systems.

This rechargeable diagnostic imaging system is a highly effective, powerful tool in emergency medical care because of its ability to examine patients who cannot be easily moved to a radiography room due to infectious concerns or physical difficulties.

A Shimadzu service engineer setting up a mobile x-ray system delivered urgently for COVID-19 diagnosis.
Related Information:

Message from Shimadzu People

Manufacturing Department Shimane Shimadzu Corporation Mikio Adachi

Manufacturing Department, Shimane Shimadzu Corporation
Mikio Adachi

Increasing the Production of X-ray Systems Needed Urgently

Shimane Shimadzu (located in Shimane Prefecture, Japan), which manufactures medical imaging equipment, has been directing its energies towards production increase of the Digital Mobile X-ray System. The COVID-19 pandemic has brought about an urgent need for this equipment in medical institutions around the world.

A patient with an infectious disease such as COVID-19 risks infecting others if they need to go to a general x-ray examination room. There is a need for equipment that can be moved to an isolation ward or intensive care unit (ICU) so that x-rays can be taken at the patient's bedside.

In response to this rapid increase in demand, Shimane Shimadzu was quick to draw up a plan in early February 2020 to increase production, and this plan has been in place since March. By changing the layout of our factory and allocating workers from other product lines, we work hard to maintain a production output double that of usual. In June, travel restrictions between prefectures were eased, allowing staff from Shimadzu Kyoto factory to come and support us, further bolstering the production line.

Looking back on our struggle, we faced a situation in late March where the supply of equipment components seemed to be stagnant, due to our factory outside Japan that manufactures important parts being closed by the government order to prevent the spread of coronavirus. But that problem was resolved with the support of Shimadzu's Kyoto factory and partner companies, and now our production is proceeding smoothly.

In order to deliver that required equipment to medical institutions around the world as quickly as possible, we will continue our efforts to maximize our manufacturing output while taking measures to prevent infection.

Message from Shimadzu People

Service Engineer, Shimadzu Medical Systems (Oceania) Pty. Ltd, NSW, Australia Yogesh Kaleliya

Service Engineer,
Shimadzu Medical Systems (Oceania) Pty. Ltd,
NSW, Australia
Yogesh Kaleliya

* This interview was conducted in mid-June 2020.

Provide best field support for healthcare workers

Being in the service team my role is to support the healthcare team by completing installation as planned and making sure our equipment is running as per the high standards set by Shimadzu to provide quality care to customers.

Due to the coronavirus, sites with our systems have been extremely busy, and as the systems are being used more than usual, maintenance becomes more and more important. Also maintaining social distancing can sometimes be challenging inside the office and at the hospital.

So, what comes next? Will this become the new normal? When will we find a vaccine? When will we be able to travel domestic and international? There is lot of uncertainty and unanswered questions in my mind and I am sure there is in everyone’s mind as well. I believe this is a time when we need to stay together and look after our wellbeing and stay in touch with our family, friends and colleagues.

In my recent install when I handed over the system the clinicians were very happy with the results that can be achieved using our systems. I feel proud to see that our systems are being used in the frontline COVID-19 clinics and are helping clinicians effectively treat patients. Also, I am lucky to be a part of a motivated team led by a very supportive manager who helps us maintain work life balance during this busy times.

Healthcare workers are true heroes who have risked their own lives to save ours. Their tireless efforts will contribute to a reduction in the number of new cases and the COVID-19 may become less of people’s concern. However, we should never forget the selfless care and dedication of our frontline Healthcare workers who helped us come out stronger on the other side.

Drug Analysis and Research
Supporting Assay of the Drug Candidates for COVID-19

The development of COVID-19 drugs is an urgent task for humankind. Many laboratories and hospitals around the world have been conducting studies to find a solution against the spread of COVID-19. Several drugs, such as Remdesivir, Favipiravir or Hydroxychloroquine, are on the test bench.

Alsachim, a Shimadzu group company located in France with expertise in the R&D of stable isotope labeled compounds, has synthesized the internal standards necessary for the assay of the drug candidates tested against COVID-19.

COVID-19 Drug Candidates
Corresponded by Alsachim Stable Isotope Reagents
Generic name Use
Remdesivir Ebola virus disease
Fabipiravir Novel influenza
Nafamostat Acute Pancreatitis
Lopinavir, Ritonavir HIV
Chloroquine Antimalarial agent
Hydroxychloroquine Antimalarial, Systemic Lupus Erythematosus
Stable isotope reagent corresponding to Remdesivir

* Research Use Only. Not for Use in Diagnostic Procedures.
* To confirm the details of your regional availability, please contact your local representative.

Shimadzu and Alsachim are supporting drug development and clinical trials by providing instruments and internal standards for LC/MS of anti-COVID-19 drug candidates.

CLAM-2030

LC-MS
for Faster, Safer, and Simpler Bioanalysis

Product Information

* Research Use Only. Not for Use in Diagnostic Procedures.

Quality & Safety Testing
Supporting Quality Control of Hygiene Products

Human safety and health are of utmost importance during this period of COVID-19.

The World Health Organization (WHO) recommends the practice of good hand hygiene as one of the basic protective measures against COVID-19. This includes washing hands with soap and water or cleaning your hands with alcohol-based hand sanitizer.

Shimadzu analytical instruments support quality testing and safety inspection of sanitizers and disinfectants to ensure and protect our health and well-being.

For more information:
Testing of pharmacopoeial ethanol (disinfectant ethanol)

This page may contain references to products that are not available in your country.
Please contact us to confirm the availability of these products in your country.

Contact Us